Variability of the IFN-γ ELISpot assay in the context of proficiency testing and bridging studies

about

Variability of the IFN-γ ELISpot assay in the context of proficiency testing and bridging studies

Item

http://www.wikidata.org/entity/Q36880258

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Variability of the IFN-γ ELISp ...... y testing and bridging studies

@en

type

Item

label

Variability of the IFN-γ ELISp ...... y testing and bridging studies

@en

prefLabel

Variability of the IFN-γ ELISp ...... y testing and bridging studies

@en

P1476

Variability of the IFN-γ ELISp ...... y testing and bridging studies

@en

P2093

Ana M Sanchez

http://www.w3.org/2001/XMLSchema#string

Mark Berrong

http://www.w3.org/2001/XMLSchema#string

Thomas N Denny

http://www.w3.org/2001/XMLSchema#string

Wes Rountree

http://www.w3.org/2001/XMLSchema#string

P2860

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

Response definition criteria for ELISPOT assays revisited

Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials.

Statistical methods for the assessment of EQAPOL proficiency testing: ELISpot, Luminex, and Flow Cytometry.

Toward development of a comprehensive external quality assurance program for polyfunctional intracellular cytokine staining assays.

Development and implementation of a proficiency testing program for Luminex bead-based cytokine assays.

The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay

Measurement of cytokine release at the single cell level using the ELISPOT assay.

Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination.

Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials.

P304

69-76

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JIM.2016.03.004

http://www.w3.org/2001/XMLSchema#string

P478

433

http://www.w3.org/2001/XMLSchema#string

P50

Guido Ferrari

P577

2016-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27021273

http://www.w3.org/2001/XMLSchema#string

P932

4860083

http://www.w3.org/2001/XMLSchema#string